ALX Oncology Reports $17.9M Net Loss, Significant Cash Increase in Latest 10-Q Filing

ALX Oncology Holdings Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company recorded a net loss of $17.9 million, a 42% decrease from the $30.8 million loss reported in the same period last year. This improvement was attributed to a reduction in total operating expenses, which fell by 40% to $19.0 million, down from $31.8 million in the prior year. The decrease in expenses was primarily driven by a 43% reduction in research and development costs, which amounted to $13.6 million, and a 32% decline in general and administrative expenses, totaling $5.4 million.

In terms of liquidity, ALX Oncology's cash and cash equivalents increased significantly to $32.3 million as of March 31, 2026, compared to $16.4 million at the end of the previous fiscal year. The company also reported a substantial rise in total assets, which reached $178.3 million, up from $59.0 million at the end of 2025. This increase was largely due to a successful equity offering in February 2026, which generated approximately $140.4 million in net proceeds. The company issued 76.98 million shares of common stock at an offering price of $1.57 per share, alongside pre-funded warrants.

Operationally, ALX Oncology is advancing its clinical pipeline, which includes the CD47 blocker evorpacept and the EGFR-targeted antibody-drug conjugate ALX2004. The company is currently conducting multiple clinical trials, including the Phase 2 ASPEN-09-Breast trial, which evaluates evorpacept in combination with trastuzumab and chemotherapy for HER2-positive metastatic breast cancer. The company has also made strategic decisions to streamline its clinical development programs, focusing resources on the most promising trials.

As of March 31, 2026, ALX Oncology's total liabilities decreased to $27.0 million from $33.1 million at the end of 2025, reflecting a reduction in current liabilities. The company’s stockholders' equity surged to $151.3 million, up from $26.0 million, primarily due to the recent equity offering. The company continues to face challenges in securing additional funding to support its ongoing research and development efforts, as it has not yet generated revenue from product sales. Management anticipates that it will need to raise further capital to sustain operations and advance its clinical programs.

Looking ahead, ALX Oncology expects to incur significant expenses as it continues to advance its product candidates through clinical trials and pursue regulatory approvals. The company believes that its existing capital resources will be sufficient to fund its operating requirements for at least the next twelve months. However, it acknowledges the need for additional funding to fully implement its business plan, which may involve equity offerings, debt financing, or strategic partnerships.